Breaking Down Cardiff Oncology, Inc. (CRDF) Financial Health: Key Insights for Investors

Are you keeping a close watch on biotech stocks, especially those pioneering cancer therapies? Then you might be asking: How is Cardiff Oncology, Inc. (CRDF) positioned financially to advance its clinical programs? Did you know that as of December 31, 2024, they reported approximately $91.7 million in cash and short-term investments, including a recent $40 million capital raise? But, with operating activities using $10.3 million in Q4 2024 alone, how long can this runway last, and what does it mean for investors eyeing their lead program, ONVANSERTIB, showing promising results in metastatic colorectal cancer trials?

Cardiff Oncology, Inc. (CRDF) Revenue Analysis

Understanding Cardiff Oncology, Inc.'s financial health requires a detailed look at its revenue streams, growth, and segment contributions. As a clinical-stage biotechnology company, Cardiff Oncology, Inc. does not currently have products approved for sale and thus has not generated revenue from product sales. Instead, the company primarily relies on revenue generated from licensing agreements, collaborations, and government grants.

Because Cardiff Oncology, Inc. is focused on developing onvansertib, it has not generated revenue from product sales. Instead, its financial strategy includes potential future revenue streams from:

• Strategic collaborations
• Licensing agreements
• Government grants

As of the fiscal year 2024, Cardiff Oncology, Inc. reported $0 in revenue. Given its status as a clinical-stage company without approved products, this is consistent with its business model, which relies on external funding and strategic partnerships to advance its drug development programs.

Here’s a breakdown of what investors should consider regarding Cardiff Oncology, Inc.'s revenue:

• Primary Revenue Sources: Currently, Cardiff Oncology, Inc.'s revenue primarily comes from collaborative agreements and interest income.
• Year-over-Year Revenue Growth Rate: There is no year-over-year revenue growth from product sales to analyze, as the company is pre-revenue.
• Contribution of Business Segments: As a single-focus company, all potential future revenue is tied to the success of onvansertib and any other compounds they may develop.
• Changes in Revenue Streams: Any significant changes would likely stem from new partnerships, grants, or licensing agreements.

For more insights into Cardiff Oncology, Inc.'s strategic goals, check out: Mission Statement, Vision, & Core Values of Cardiff Oncology, Inc. (CRDF).

Cardiff Oncology, Inc. (CRDF) Profitability Metrics

Analyzing Cardiff Oncology, Inc.'s financial health involves a detailed look at its profitability metrics. Profitability is a key indicator of a company's financial performance and its ability to generate earnings relative to its revenue, operating costs, and assets. For Cardiff Oncology, understanding these metrics provides insights into its operational efficiency and overall financial stability.

As of the fiscal year 2024, comprehensive profitability data for Cardiff Oncology, Inc. requires a thorough examination of available financial reports and industry benchmarks. Given the dynamic nature of financial data, investors and analysts should refer to the latest filings and reports for the most up-to-date information.

Typically, the following profitability metrics are crucial for evaluating a company like Cardiff Oncology:

• Gross Profit Margin: This ratio indicates the percentage of revenue that exceeds the cost of goods sold (COGS). It reflects how efficiently a company manages its production costs.
• Operating Profit Margin: This margin measures the percentage of revenue remaining after deducting operating expenses (e.g., wages, depreciation, and administrative costs). It provides insights into the company's efficiency in managing operational costs.
• Net Profit Margin: The net profit margin shows the percentage of revenue that remains as net income after all expenses, including interest and taxes, are deducted. It is a comprehensive measure of overall profitability.

Trends in profitability over time are also essential. Analyzing these metrics across multiple periods can reveal whether Cardiff Oncology's profitability is improving, declining, or remaining stable. Comparing these ratios with industry averages provides context and helps determine whether the company is performing better or worse than its peers.

Operational efficiency is another critical area to assess. Metrics related to cost management and gross margin trends can indicate how well Cardiff Oncology controls its expenses and maximizes its revenue potential. For instance, a rising gross margin might suggest improved cost management or increased pricing power.

For detailed financial analysis and further insights, you can refer to: Breaking Down Cardiff Oncology, Inc. (CRDF) Financial Health: Key Insights for Investors

Cardiff Oncology, Inc. (CRDF) Debt vs. Equity Structure

Understanding how Cardiff Oncology, Inc. (CRDF) finances its growth involves analyzing its debt and equity structure. This provides insights into the company's financial risk and stability, which are crucial for investors. Here's a breakdown of key aspects:

As of the fiscal year 2024, details on Cardiff Oncology, Inc.'s (CRDF) debt levels, debt-to-equity ratio, recent financing activities, and the balance between debt and equity are essential to gauge its financial strategy. Investors should scrutinize these elements to form a comprehensive view.

Here's what to consider regarding Cardiff Oncology, Inc.'s (CRDF) debt and equity:

• Overview of Debt Levels: Examining both long-term and short-term debt provides a clear picture of Cardiff Oncology, Inc.'s (CRDF) financial obligations.
• Debt-to-Equity Ratio: This ratio is a critical metric for assessing the balance between debt and equity. It indicates the extent to which the company is using borrowed money versus its own funds to finance its assets. A high ratio might suggest higher financial risk.
• Recent Financing Activities: Any recent debt issuances, credit ratings, or refinancing activities can significantly impact the company's financial health. New debt can fuel growth but also increase financial strain.
• Balancing Debt and Equity: How Cardiff Oncology, Inc. (CRDF) strategically uses debt and equity to fund its operations and growth is vital. Effective balance ensures financial flexibility and sustainability.

For additional insights into the company's guiding principles, refer to Mission Statement, Vision, & Core Values of Cardiff Oncology, Inc. (CRDF).

Cardiff Oncology, Inc. (CRDF) Liquidity and Solvency

When evaluating Cardiff Oncology, Inc. (CRDF), understanding its liquidity and solvency is crucial for investors. These metrics provide insights into the company's ability to meet its short-term and long-term obligations, reflecting its financial stability and risk profile.

Assessing Cardiff Oncology, Inc.'s Liquidity:

Liquidity ratios help determine if Cardiff Oncology, Inc. has enough liquid assets to cover its immediate liabilities. Key ratios include:

• Current Ratio: This ratio measures a company's ability to pay short-term obligations with its current assets. While specific 2024 data for Cardiff Oncology, Inc.'s current ratio isn't available, a ratio above 1 generally indicates good liquidity.
• Quick Ratio (Acid-Test Ratio): This ratio is similar to the current ratio but excludes inventory, providing a more conservative view of liquidity. Again, without precise 2024 figures, a quick ratio at or above 1 suggests the company can comfortably meet its short-term liabilities.

Working Capital Trends:

Analyzing the trend of Cardiff Oncology, Inc.'s working capital (current assets minus current liabilities) offers insights into its operational efficiency and short-term financial health. An increasing working capital balance typically indicates improving liquidity, while a decreasing balance may signal potential challenges.

Cash Flow Statements Overview:

The cash flow statement is vital for understanding how Cardiff Oncology, Inc. generates and uses cash. It's divided into three main sections:

• Operating Cash Flow: This reflects the cash generated from the company's core business activities. Consistent positive operating cash flow is a sign of financial health.
• Investing Cash Flow: This section shows cash used for investments in assets like property, plant, and equipment (PP&E). Negative investing cash flow often indicates the company is investing in its future growth.
• Financing Cash Flow: This includes cash from activities like borrowing, issuing stock, and paying dividends. Monitoring this section helps understand how the company is funding its operations and growth.

Potential Liquidity Concerns or Strengths:

Based on available data up to April 2025, Cardiff Oncology, Inc. may exhibit typical liquidity patterns for a biotechnology company, balancing research and development expenses with funding activities. Investors should monitor these trends for any significant shifts that could impact the company's financial stability.

For further insights into Cardiff Oncology, Inc.'s financial health, you can refer to this analysis: Breaking Down Cardiff Oncology, Inc. (CRDF) Financial Health: Key Insights for Investors

Cardiff Oncology, Inc. (CRDF) Valuation Analysis

Determining whether Cardiff Oncology, Inc. (CRDF) is overvalued or undervalued requires a multifaceted approach, incorporating various financial ratios, stock performance analysis, and analyst opinions.

Valuation Ratios:

Several key ratios provide insights into Cardiff Oncology's valuation:

• Price-to-Earnings (P/E Ratio): As of April 2025, CRDF's P/E ratio is not applicable (N/A) or negative, due to negative earnings.
• Price-to-Book (P/B Ratio): The P/B ratio is around 2.29 to 3.48. A higher P/B ratio may suggest the stock is overvalued, relative to its book value.
• Enterprise Value-to-EBITDA (EV/EBITDA): The EV/EBITDA ratio is negative (-2.42 to -3.22) or not applicable (NM), which can occur when EBITDA is negative.

Stock Price Trends:

Analyzing stock price movements over the past year provides context on market sentiment:

• Over the last 52 weeks, the stock price has decreased by approximately -34.48% to -37.91%.
• The 52-week high is $5.64, while the 52-week low is $2.01.
• As of April 17, 2025, the stock price is around $2.85.

Dividend Yield and Payout Ratios:

Cardiff Oncology does not currently pay dividends, so dividend yield and payout ratios are 0% or N/A.

Analyst Consensus:

Analyst ratings and price targets offer external validation of the company's valuation:

• The consensus rating for CRDF is a 'Strong Buy' or 'Buy'.
• The average analyst price target ranges from $11.67 to $15.25, implying a substantial upside potential from the current price.
• However, note that valuation results may not be accurate due to the company's negative EPS.

Additional Considerations:

Other factors to consider in the valuation analysis include:

• Market Capitalization: As of April 2025, the market capitalization is approximately $185.61 million to $190.26 million.
• Revenue: In the last 12 months, Cardiff Oncology had revenue of $683,000 to $684,000.
• Net Loss: The company experienced a net loss of -$45.43 million to -$45.46 million.

A fair value analysis conducted on April 17, 2025, suggests that Cardiff Oncology Inc. (CRDF) may not be a good investment, with a fair value of -$3.41 USD compared to a market price of $2.94 USD, indicating a -216.2% upside based on Peter Lynch's Fair Value formula. However, this result may be unreliable due to the company's negative EPS.

For further insights into the investors of Cardiff Oncology, Inc., explore this link: Exploring Cardiff Oncology, Inc. (CRDF) Investor Profile: Who’s Buying and Why?

Cardiff Oncology, Inc. (CRDF) Risk Factors

Investing in Cardiff Oncology, Inc. (CRDF) involves navigating a landscape of both internal and external risks that could significantly impact its financial health. These risks span industry competition, regulatory changes, market conditions, and specific operational and strategic challenges detailed in the company's filings.

Here's a look at some key risk factors:

• Industry Competition: The biotechnology industry is intensely competitive. Cardiff Oncology, Inc. faces competition from other companies, including those with substantially greater resources, that are developing therapies for similar indications. This competition can affect the company's ability to successfully develop and commercialize its product candidates.
• Regulatory Risks: The development, testing, manufacturing, and marketing of Cardiff Oncology, Inc.'s product candidates are subject to extensive regulation by governmental authorities in the United States and other countries. These regulations are subject to change, and new regulations could be enacted that could adversely affect the company's business.
• Market Conditions: Economic downturns or instability in financial markets could reduce the availability of capital, which could adversely affect Cardiff Oncology, Inc.'s ability to fund its operations.

Analyzing recent earnings reports and filings is crucial to understanding the specific risks the company faces. These documents often highlight operational, financial, and strategic risks that are particularly relevant to Cardiff Oncology, Inc.'s current position.

Examples of risks discussed in filings may include:

• Clinical Trial Risks: The success of Cardiff Oncology, Inc. depends heavily on the successful outcome of its clinical trials. Delays or failures in these trials can significantly impact the company's prospects.
• Funding and Capital Risks: Cardiff Oncology, Inc. requires substantial capital to fund its research and development activities. The company may need to raise additional capital through equity offerings, debt financing, or other sources. However, there is no guarantee that such funding will be available on acceptable terms, or at all.
• Reliance on Third Parties: Cardiff Oncology, Inc. relies on third parties for various aspects of its operations, including manufacturing and clinical trial management. Any problems with these third parties could adversely affect the company's business.

Mitigation strategies are essential for managing these risks. While specific strategies can vary, common approaches include:

• Diversification of Product Pipeline: Developing multiple product candidates can reduce the risk associated with the failure of any one product.
• Strategic Partnerships: Collaborating with other companies can provide access to additional resources and expertise.
• Careful Financial Planning: Maintaining a strong balance sheet and managing cash flow effectively can help the company weather economic downturns.

For more insights into Cardiff Oncology, Inc. (CRDF) and its investors, check out: Exploring Cardiff Oncology, Inc. (CRDF) Investor Profile: Who’s Buying and Why?

Cardiff Oncology, Inc. (CRDF) Growth Opportunities

For investors eyeing Cardiff Oncology, Inc. (CRDF), a thorough understanding of its growth prospects is crucial. Several factors appear poised to influence the company's trajectory, ranging from innovative product development to strategic market maneuvers.

Here's a breakdown of potential growth drivers:

• Product Innovations: Cardiff Oncology, Inc. (CRDF)'s commitment to research and development is a key growth driver. The success of new drugs or therapies in the pipeline can significantly boost revenue.
• Market Expansion: Entering new geographic markets or expanding the applications of existing products can unlock additional revenue streams.
• Strategic Partnerships: Collaborations with other companies can provide access to new technologies, markets, or funding, fueling growth.

To assess future performance, consider these projections and strategic elements:

• Revenue Growth Estimates: Keep a close watch on analysts' forecasts for Cardiff Oncology, Inc. (CRDF)'s revenue growth. These estimates reflect expectations for product adoption and market penetration.
• Earnings Projections: Earnings estimates provide insights into the company's profitability potential. Positive earnings trends can signal strong growth prospects.
• Strategic Initiatives: Monitor any strategic initiatives undertaken by Cardiff Oncology, Inc. (CRDF), such as new partnerships, acquisitions, or expansions into new therapeutic areas. These moves can significantly impact future growth.

Cardiff Oncology, Inc. (CRDF) operates in a competitive landscape. To understand its growth potential, consider these competitive advantages:

• Proprietary Technology: Unique or patented technologies can give Cardiff Oncology, Inc. (CRDF) a competitive edge.
• Strong Intellectual Property: A robust portfolio of patents and trademarks can protect the company's innovations and market position.
• Established Market Presence: A strong reputation and existing relationships with healthcare providers can facilitate product adoption.

While specific revenue growth projections and earnings estimates for Cardiff Oncology, Inc. (CRDF) beyond 2024 are not available in the provided search results, investors can find such information in financial news outlets, investor relations releases, and analyst reports. Always refer to the most recent data for informed decision-making.

Here is a brief overview of factors that can influence Cardiff Oncology, Inc. (CRDF)'s growth. For more insights into the company's values, see: Mission Statement, Vision, & Core Values of Cardiff Oncology, Inc. (CRDF).